Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Capital Employed (2017 - 2025)

Aclaris Therapeutics has reported Return on Capital Employed over the past 9 years, most recently at 0.55% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.55% for Q4 2025, up 29.0% from a year ago — trailing twelve months through Dec 2025 was 0.55% (up 29.0% YoY), and the annual figure for FY2025 was 0.47%, up 33.0%.
  • Return on Capital Employed for Q4 2025 was 0.55% at Aclaris Therapeutics, up from 0.98% in the prior quarter.
  • Over the last five years, Return on Capital Employed for ACRS hit a ceiling of 0.3% in Q3 2024 and a floor of 0.98% in Q3 2025.
  • Median Return on Capital Employed over the past 5 years was 0.49% (2024), compared with a mean of 0.52%.
  • Biggest five-year swings in Return on Capital Employed: surged 66bps in 2021 and later plummeted -68bps in 2025.
  • Aclaris Therapeutics' Return on Capital Employed stood at 0.38% in 2021, then rose by 2bps to 0.38% in 2022, then crashed by -46bps to 0.55% in 2023, then crashed by -52bps to 0.84% in 2024, then soared by 34bps to 0.55% in 2025.
  • The last three reported values for Return on Capital Employed were 0.55% (Q4 2025), 0.98% (Q3 2025), and 0.88% (Q2 2025) per Business Quant data.